Abstract
Radioiodine is an important radiopharmaceutical agent in nuclear medicine practice for the treatment of hyperthyroidism and differenciated thyroid cancer. One of the long term side effects of ionising radiation is the possibility of radiation induced malignancy. There are limited reports about malignancy after 131 I therapy for thyrotoxicosis. In this report, a case with papillary thyroid cancer after radioactive iodine (RAI) therapy for toxic thyroid nodule is presented. In this case, fine needle aspiration biopsy(FNAB) had not been done before RAI therapy and papillary carcinoma was detected four years later than the 444 MBq RAI therapy. The patient underwent bilateral total thyroidectomy and central neck dissection. After the surgery, the patient underwent 5550 MBq RAI for ablation. Summary, differentiated thyroid cancer can be found incidentally in toxic nodule or can be developed as a consequence of radioiodine therapy. FNAB must be performed for all the patients with hot or cold thyroid nodules before RAI therapy and all the patients taking RAI theraphy should be closely followed in terms of nodule growing and cancer development. J Med Cases. 2013;4(10):686-688 doi: http://dx.doi.org/10.4021/ jmc1459w
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
